| |
|
|
|
|
|
|
|||
|
Erratum
for
Changelian et al., Blood, 1 October 2009, Vol. 114, No. 14, pp. 3132.
ERRATA Changelian et al. The specificity of JAK3 kinase inhibitors. Blood. 2008;111(4):2155–2157.On pages 2155 and 2157 of the February 15, 2008, issue, an author name and his authorship contribution were omitted and there is an incorrect notation. The errors were corrected in the online version, which now differs from the print version.David A. Whipple should have been listed as the seventh author in the author list. The correct author list is shown: Paul S. Changelian,1 Deborah Moshinsky,1 Cyrille F. Kuhn,1 Mark E. Flanagan,1 Michael J. Munchhof,1 Thomas M. Harris,1 David A. Whipple,1 Jonathan L. Doty,1 Jianmin Sun,1 Craig R. Kent,1 Kelly S. Magnuson,1 David G. Perregaux,1 Perry S. Sawyer,1 and Elizabeth M. Kudlacz1 1Pfizer Global Research and Development, Groton, CT
In "Methods" on page 2155, in the second sentence under the heading "Cellular assays," "1 mg/mL final concentration" should have appeared as "1 µg/mL final concentration." The correct sentence should read: Human whole blood assay: Anti-CD3 On page 2157, the Authorship contribution of David A. Whipple was omitted. The correct Authorship section should read: Contribution: P.S.C. conceived the studies and wrote the paper; D.M. and K.S.M. performed kinase assays; C.F.K. cowrote the paper; M.E.F. and M.J.M. conceived the studies; T.M.H., J.L.D., D.A.W., and J.S. synthesized compounds; C.R.K. and D.G.P. performed cellular assays; P.S. performed in vivo assays; and E.M.K. conceived the studies and cowrote the paper.
| |||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||